SCHEMBL31455774

SCHEMBL31455774

COC(=O)c1c(F)cc(C(=O)OC(C)(C)C)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
NFKB1 P19838 1/20 0.43
XDH P47989 1/20 0.43
GFER P55789 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
FUT7 Q11130 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 1/20 0.41
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
CA14 Q9ULX7 3/20 0.40
CA7 P43166 2/20 0.40
NOTUM Q6P988 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522695 0.85 KDM4E (0.57) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL21956939 0.84 LMNA (0.39) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL25074759 0.83 CA12 (0.36) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL662974 0.82 CES2 (0.50) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL17747120 0.81 CA1 (0.54) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL10228045 0.81 TUBB1 (0.41) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL20741075 0.81 LMNA (0.42) KDM4EPOLBLMNAFUT7TDP1
SCHEMBL663524 0.80 SERPINE1 (0.43) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL9543676 0.79 MAPT (0.38) KDM4EPOLBL3MBTL1LMNAGAA
SCHEMBL16137967 0.79 MAPT (0.41) KDM4EL3MBTL1GAAMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed